08 May XenoGesis chosen as CRO partner for Medicines Discovery Catapult Virtual R&D group
Nottingham-based leading DMPK provider, XenoGesis, has been selected as a CRO partner to support the UK Medicines Discovery Catapult Virtual R&D Discovery Services platform worldwide. Based at BioCity Nottingham, XenoGesis is one of 22 world-class CROs chosen for the partnerships by the UK government’s Medicines Discovery...